Quest Diagnostics Reports on Shareholder Vote Matters

Ticker: DGX · Form: 8-K · Filed: 2025-05-22T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: DGX

TL;DR

Quest Diagnostics filed an 8-K about a shareholder vote. Details to follow.

AI Summary

Quest Diagnostics Inc. filed an 8-K on May 22, 2025, reporting on matters submitted to a vote of security holders as of May 15, 2025. The filing indicates a submission of matters to a vote, but does not provide details on the specific proposals or outcomes.

Why It Matters

This filing informs shareholders about important corporate actions and decisions that have been put to a vote, impacting the company's governance and future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not contain information that would immediately impact the company's financial health or stock price.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Quest Diagnostics' security holders?

The filing does not specify the exact matters submitted to a vote, only that such matters were reported on as of May 15, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 15, 2025.

What is the principal executive office address for Quest Diagnostics Inc.?

The principal executive office is located at 500 Plaza Drive, Secaucus, NJ 07094.

What is Quest Diagnostics' state of incorporation?

Quest Diagnostics Inc. is incorporated in Delaware.

What is the filing date of this Current Report on Form 8-K?

This Current Report on Form 8-K was filed on May 22, 2025.

From the Filing

0001022079-25-000154.txt : 20250522 0001022079-25-000154.hdr.sgml : 20250522 20250522062825 ACCESSION NUMBER: 0001022079-25-000154 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250515 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 25974690 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 dgx-20250515.htm 8-K dgx-20250515 0001022079 false 0001022079 2025-05-15 2025-05-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) : May 15, 2025 Quest Diagnostics Inc orporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I.R.S. Employer Identification No.) 500 Plaza Drive Secaucus, NJ 07094 (Address of principal executive offices) (Zip Code) (973) 520-2700 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07 Submission of Matters to a Vote of Security Holders (a)           The following is a summary of the voting results for each matter presented to the stockholders at the 2025 Annual Meeting of Stockholders which was held on May 15, 2025. (b)           The following nominees for the office of director were elected for terms expiring at the 2026 Annual Meeting of Stockholders, by the following votes: For Against Abstain Broker Non-Vote Robert B. Carter 94,240,720  298,067  262,706  8,154,907  James E. Davis 86,900,389 7,692,258 208,844 8,154,909 Luis A. Diaz, Jr., M.D. 94,207,193 343,702 250,599 8,154,906 Tracey C. Doi 94,067,950 421,307 312,234 8,154,909 Vicky B. Gregg 87,477,670 7,005,519 318,301 8,154,910 Wright L. Lassiter, III 94,032,6

View on Read The Filing